Drug Profile
Research programme: autoimmune disease therapeutics - Bayhill Therapeutics
Alternative Names: BHT-8001Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bayhill Therapeutics
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders